Biodexa Pharmaceuticals Plc

Research Biodexa Pharmaceuticals Plc (BDRX) on Bullrun: market cap USD 2.13M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBDRX
• ExchangeNASDAQ
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.13M
• Financial periodQ4 2025
• Net income-USD 6.38M
• Free cash flow-USD 6.28M

Valuation Snapshot

latest market cap is USD 2.13M.

About Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Frequently asked questions

What is Biodexa Pharmaceuticals Plc's market cap?

Biodexa Pharmaceuticals Plc's market capitalization is USD 2.13M.

What does Biodexa Pharmaceuticals Plc do?

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer.